DK3467509T3 - Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose - Google Patents

Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose

Info

Publication number
DK3467509T3
DK3467509T3 DK18204837.1T DK18204837T DK3467509T3 DK 3467509 T3 DK3467509 T3 DK 3467509T3 DK 18204837 T DK18204837 T DK 18204837T DK 3467509 T3 DK3467509 T3 DK 3467509T3
Authority
DK
Denmark
Prior art keywords
cell
diagnosis
treatment
specific
multiple sclerosis
Prior art date
Application number
DK18204837.1T
Other languages
English (en)
Inventor
Stefanie Kuerten
Paul V Lehmann
Original Assignee
Cellular Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Tech Ltd filed Critical Cellular Tech Ltd
Application granted granted Critical
Publication of DK3467509T3 publication Critical patent/DK3467509T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rehabilitation Therapy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DK18204837.1T 2011-05-04 2012-05-03 Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose DK3467509T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482365P 2011-05-04 2011-05-04
EP12782351.6A EP2707013B1 (en) 2011-05-04 2012-05-03 Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
DK3467509T3 true DK3467509T3 (da) 2026-02-09

Family

ID=47139471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18204837.1T DK3467509T3 (da) 2011-05-04 2012-05-03 Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose

Country Status (5)

Country Link
US (2) US11340224B2 (da)
EP (2) EP3467509B1 (da)
DK (1) DK3467509T3 (da)
FI (1) FI3467509T3 (da)
WO (1) WO2012154215A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
EP3123176A4 (en) * 2014-03-23 2018-04-25 The Regents of the University of Colorado Diagnosis of multiple sclerosis in human and animal subjects
US12458683B2 (en) 2015-03-09 2025-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use
EP3268382B1 (en) * 2015-03-09 2021-05-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use
ES3014985T3 (en) * 2016-08-12 2025-04-28 Immunowork Llc Diagnosis, prevention, and/or treatment of autoimmune diseases
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN111272998A (zh) * 2020-01-09 2020-06-12 天津天海新域生物科技有限公司 一种同时检测中枢脱髓鞘自身抗体aqp4、mog和mbp的方法
WO2021212013A2 (en) 2020-04-17 2021-10-21 Op-T Llc Bioactive peptides and methods of use thereof
CN112362877B (zh) * 2020-10-27 2024-04-12 江苏先声医学诊断有限公司 一种mbp重组蛋白以及其应用
EP4396239A4 (en) * 2021-08-31 2025-11-05 Cellular Tech Ltd DETECTION OF B LYMPHOCYTE ANTIBODY RESPONSES IN PATIENTS WITH HEMOPHILIA AND ASSOCIATED TREATMENT

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013089A1 (en) * 1993-11-10 1995-05-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Compositions and method for stimulating antibody release by b lymphocytes
US20040043431A1 (en) * 2002-08-29 2004-03-04 Aristo Vojdani Diagnosis of multiple sclerosis and other demyelinating diseases
US7598093B2 (en) 2003-07-23 2009-10-06 Ctl Analyzers, Llc Nanoparticle and microparticle based detection of cellular products
BRPI0510915A (pt) 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
US7858309B2 (en) * 2006-02-07 2010-12-28 Dianovix, Inc. Method for differentiating between multiple sclerosis subtypes
EP2057998A1 (en) * 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
EP2707013A4 (en) 2014-11-12
US11340224B2 (en) 2022-05-24
EP3467509B1 (en) 2025-11-26
EP3467509A1 (en) 2019-04-10
US20140255346A1 (en) 2014-09-11
WO2012154215A1 (en) 2012-11-15
FI3467509T3 (fi) 2026-02-11
US20190072551A1 (en) 2019-03-07
EP2707013A1 (en) 2014-03-19
EP2707013B1 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
DK3467509T3 (da) Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose
IL288203A (en) Meditopes and meditope-binding antibodies and uses thereof
LTC2785375I2 (lt) Anti-pd-l1 antikūnai ir jų panaudojimas
EP2769012A4 (en) DAMAGE MECHANISM AND USE METHOD THEREFOR
HUE044591T2 (hu) Anti-CD40 antitestek és alkalmazásuk
HUE037700T2 (hu) OX40-hez kötõdõ ellenanyagok és felhasználásuk
EP2726016A4 (en) DIAGNOSTIC METHOD AND DEVICE
LT2794654T (lt) Anti-phf-tau antikūnai ir jų panaudojimas
BR112014010175A2 (pt) unidades de filtro, componentes e recursos destas e métodos de uso e construção
HUE053545T2 (hu) Humán immundeficiencia vírus semlegesítõ antitestek és eljárások alkalmazásukra
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
EP2561677A4 (en) DEVICE AND CORRESPONDING METHODS
EP2634556A4 (en) SAMPLING DEVICE
DK2580243T3 (da) Antibodies against human cd38
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
EP2838468A4 (en) INTRAORAL LIGHT THERAPY DEVICES AND METHOD FOR THEIR USE
DK2821415T3 (da) Antistof mod anti-lipoarabinomannan og immunoassay til syrefast bacillær infektion under anvendelse af antistoffet
EP2795690A4 (en) ELECTRON TUNING DEVICE AND RELATED METHODS
EP2742532A4 (en) DEVICE AND CORRESPONDING METHODS
PT2618835T (pt) Epítopos de célula t e recetores de célula t específicos de antigénio
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
IL231777A0 (en) Antibodies against tl1a and uses thereof
EP3546481C0 (en) ANTI-INTERLEUKIN 22 ANTIBODIES (IL-22) AND THEIR USES
EP2673381A4 (en) BIOSONDES AND METHOD FOR THEIR USE
EP2799540A4 (en) HUMAN ARGINASE AND PEGYLATED HUMAN ARGINASE AND USE THEREOF